Nephrotic Syndrome/Focal Segmental Glomerulosclerosis

NY Approved

Test Overview

Clinical Utility

  • Molecular confirmation of a clinical diagnosis
  • Development of appropriate evaluation and management plan
  • Evaluation of family members as possible donors for kidney transplantation
  • Testing of at-risk relatives for specific known variant(s) previously identified in an affected family member
  • Genetic counseling and recurrence risk assessment

Test Details

Genes

ACTN4, ADCK4(COQ8B), ALG1, ANLN, APOL1, ARHGAP24, ARHGDIA, CD2AP, COL4A3, COL4A4, COL4A5, COQ2, COQ6, CRB2, CUBN, DGKE, EMP2, FAN1, FAT1, FN1, GLA, INF2, ITGA3, ITGB4, KANK1, KANK2, KANK4, LAMB2, LMX1B, MAGI2, MYH9, MYO1E, NEIL1, NPHP1, NPHS1, NPHS2, NUP107, NUP205, NUP93, OCRL, PAX2, PDSS2, PLCE1, PMM2, PTPRO, SCARB2, SGPL1, SMARCAL1, STS, TBC1D8B, TRPC6, TTC21B, WDR73, WT1, XPO5

Conditions

  • Alport Syndrome
  • Chronic Kidney Disease Risk
  • Focal Segmental Glomerulosclerosis
  • Nephrotic Syndrome

Lab Method

  • Capillary Sequencing
  • Deletion/Duplication Analysis
  • Next-Gen Sequencing

Ordering Information

Important Information

Test is designed to identify G1 and G2 risk alleles only in the APOL1 gene
Test Code: TG99
CPT Codes*: 81405x2, 81406x2, 81407x1, 81408x2, 81479x3
ABN Required: No
Turnaround Time**: 4 weeks
Preferred Specimen: 2-5 mL Blood - Lavender Top Tube
Alternative Specimen: Buccal Swabs | Extracted DNA

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.

Resources

Test Documents

Billing

Targeted Variant Testing

FAQs